ZENON 40 mg / 10 mg tabletti, kalvopäällysteinen Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

zenon 40 mg / 10 mg tabletti, kalvopäällysteinen

sanofi oy - rosuvastatinum calcicum,ezetimibum - tabletti, kalvopäällysteinen - 40 mg / 10 mg - rosuvastatiini ja etsetimibi

Nuceiva Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

nuceiva

evolus pharma b.v. - botuliinitoksiini tyyppi a - ihon vanhenemista - muut lihasrelaksantit, perifeerisesti vaikuttavat aineet - tilapäisesti vuonna ulkonäkö on kohtalainen tai vaikea pystysuoran rivit kulmakarvojen välissä nähnyt korkeintaan paheksua (glabellaariuurteita), kun vakavuus edellä kasvojen juonteita on tärkeä psykologinen vaikutus aikuisilla alle 65-vuotiaille.

Adrenalin Aguettant 1 mg/ml injektioneste, liuos, esitäytetty ruisku Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

adrenalin aguettant 1 mg/ml injektioneste, liuos, esitäytetty ruisku

laboratoire aguettant - adrenaline tartrate - injektioneste, liuos, esitäytetty ruisku - 1 mg/ml - adrenaliini

Enspryng Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

enspryng

roche registration gmbh - satralizumab - neuromyelitis optica - immunosuppressantit - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.

Ponvory Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

ponvory

janssen-cilag international n.v.    - ponesimod - multippeliskleroosi, relapsoiva-remittoiva - immunosuppressantit - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Apexxnar Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

apexxnar

pfizer europe ma eeig - pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 3, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6a, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 8, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 10a, pneumococcal polysaccharide serotype 11a, pneumococcal polysaccharide serotype 12f, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 15b, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19a, pneumococcal polysaccharide serotype 19f, pneumococcal polysaccharide serotype 22f, pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 33f - pneumokokki-infektiot - rokotteet - active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. katso kohdat 4. 4 ja 5. 1 tietoa tiettyjen pneumokokki-serotyyppien suojaamisesta. apexxnar should be used in accordance with official recommendations. .

Letybo 50 U injektiokuiva-aine, liuosta varten Phần Lan - Tiếng Phần Lan - Fimea (Suomen lääkevirasto)

letybo 50 u injektiokuiva-aine, liuosta varten

croma-pharma gmbh - bakteerit botulinum a-tyypin neurotoksiinia monimutkainen (900 kd) - injektiokuiva-aine, liuosta varten - 50 u - botuliinitoksiini

Briumvi Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

briumvi

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunosuppressantit - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Talvey Liên Minh Châu Âu - Tiếng Phần Lan - EMA (European Medicines Agency)

talvey

janssen-cilag international n.v. - talquetamab - multiple myeloma - antineoplastiset aineet - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.